Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In order to inform the public decision on the containment strategy and knowledge of the intensity of the epidemic during post-containment, estimates of the share of the population infected with the SARS-CoV-2 virus responsible for COVID-19 disease at the territorial level are needed as soon as possible. The aim of the study is to estimate the prevalence of positive anti-SARS-CoV-2 serologies by detection of IgT-total antibodies (IgM/IgA/IgG) in the general population of the Grand Nancy Metropolitan area. A study of seroprevalence and symptom collection, or absence of symptoms, on a cluster (household) sample of the Grand Nancy Metropolitan population randomly selected will be conducted. The target population consists of all the inhabitants of the Grand Nancy Metropolitan area, from which a sample is drawn from the electoral lists (households) in a random manner to ensure representativeness. In order to ultimately include 2000 people in the study
Description: Anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area
Measure: Anti-SARS-CoV-2 IgT (IgM/IgA/IgG) seropositivity Time: through study completion, an average of 4 hoursDescription: To estimate the proportion of occurrence of an episode of clinical symptoms since the beginning of the epidemic among seropositive people using self report questionnaires.
Measure: Proportion of asymptomatic, symptomatic cases among seropositive people Time: through study completion, an average of 4 hoursDescription: To estimate the proportion of asymptomatic cases (asymptomatic fraction) by the proportion of seropositive individuals who did not show any sign or symptom of COVID-19 since the beginning of the epidemic in France (mid-February).
Measure: Proportion of asymptomatic cases among seropositive people Time: through study completion, an average of 4 hoursDescription: To understand susceptibility factors to infection by comparing infected and uninfected persons on the basis of age, sex, weight status, smoking status, occupation and education.
Measure: Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status. Time: through study completion, an average of 4 hoursDescription: Determining the prevalence of seropositive people according to the level of social disadvantage
Measure: Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score Time: through study completion, an average of 4 hoursDescription: To estimate the prevalence of infected households
Measure: Proportion of infected households Time: through study completion, an average of 4 hoursDescription: To provide knowledge on intra-household dissemination
Measure: Anti-SARS-CoV-2 IgT seropositivity in the household Time: through study completion, an average of 4 hoursDescription: To develop symptom association profiles in seropositive subjects
Measure: Clinical expression patterns of infection by symptom/antibody association Time: through study completion, an average of 4 hoursDescription: To study the serum distribution of seropositive people, particularly in each symptom typology group.
Measure: Serological Response to Infection Time: through study completion, an average of 4 hoursDescription: To use the results of the SARS-CoV-2 seroprevalence testing campaign and questionnaires to refine our knowledge of the current and future situation and make better projections with better calibrated mathematical models of SIR infectious diseases.
Measure: Anti-SARS-CoV-2 IgT seropositivity Time: through study completion, an average of 4 hoursDescription: 10. To evaluate the in vitro neutralisation capacity of the viral infectivity of the antibodies detected.
Measure: • Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum. Time: through study completion, an average of 4 hours